• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: BNT162b2 mRNA vaccine shows benefit against symptomatic and asymptomatic SARS-CoV-2 infection

byConstance Wu
May 25, 2021
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort.

2. BNT162b2 mRNA vaccine showed an effectiveness of 70% 21 days after a single dose.

Evidence Rating Level: 2 (Good) 

Study Rundown: The BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 nCoV-19 adenoviral (Oxford-AstraZeneca) COVID-19 vaccines have been rapidly rolled out in the UK since December 2020. However, population-level vaccine effectiveness studies are needed to assess the impact of coronavirus vaccination and inform developments of public health policy. This prospective cohort study (SIREN) aimed to describe factors associated with both BNT162b2 and ChAdOx1 nCoV-19 vaccine coverage and early effectiveness of the BNT162b2 vaccine against symptomatic and asymptomatic infection in a large-scale cohort of healthcare workers in UK. The primary outcome for vaccine coverage analysis was the binary ever vaccinated variable (defined as having ³ 1 vaccine dose recorded between Dec 8, 2020, and Feb 5, 2021), while that for vaccine effectiveness analysis was PCR-confirmed SARS-CoV-2 infection (defined as a new PCR positive result for the negative cohort and reinfection in the positive cohort at the time of follow-up). According to study results, the BNT162b2 vaccine was effective against both symptomatic and asymptomatic SARS-CoV-2 infection in working-age adults. A limitation of this study may be the lack of objective functional assessments, such as baseline respiratory function, as the major outcomes considered were recorded through online questionnaires. Nonetheless, it provides valuable insight into the effectiveness of the BNT162b2 vaccine in a population-level cohort.

Click to read the study in The Lancet

Relevant Reading: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

In-depth [prospective cohort]: By Dec 7, 2020, 29 378 patients were assessed for eligibility across 104 hospital sites in the UK. Included patients were healthcare workers, support staff, and administrative staff (aged ³ 18 years) who provided written consent and were able to complete the 12-month follow-up. Those with no PCR tests or insufficient PCR and antibody data were excluded. Altogether, 23 324 patients (8203 [35%] in the positive cohort and 15 121 [65%] in the negative cohort) met the inclusion criteria. The median patient age was 46.1 years (interquartile range [IQR] 36.0-54.1) and majority (84%) were female.

RELATED REPORTS

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

Unvaccinated status increases risk of long COVID symptoms

The 2 Minute Medicine Podcast Episode 6

The total follow-up time was from Dec 7, 2020, to Feb 5, 2021, equivalent to 1 106 905 person-days (396 318 person-days vaccinated and 710 587 person-days unvaccinated). By Feb 5, 2021, 89% of patients (n=20 641) received at least one dose, with 94% receiving the BNT162b2 vaccine. Having a previous infection (adjusted odds ratio [aOR] 0.59, 95% confidence interval [CI] 0.54-0.64), being female (aOR 0.72, 95% CI 0.63-0.82), and age < 35 (aOR 0.78, 95% CI 0.64-0.96) were associated with significantly lower vaccine coverage. Compared to the vaccinated group, the unvaccinated group reported a substantially greater number of new infections (71 cases vs. 977 cases) during follow-up (adjusted hazard ratio 0.30, 95% CI 0.15-0.45). In the unvaccinated cohort, 543 (56%) patients had typical COVID-19 symptoms and 140 (14%) were asymptomatic 14 days prior to PCR-positive result, compared with 29 (36%) and 15 (19%) in the vaccinated cohort. A single dose of the BNT162b2 vaccine showed 70% (95% CI 55-85) effectiveness after three weeks. Findings from this study suggest that a single dose provides substantial efficacy against both symptomatic and asymptomatic COVID-19 infections.

Image: PD 

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bnt162b2CoronavirusmrnamRNA vaccinepfizerSARS-CoV-2vaccine
Previous Post

Tezepelumab reduced annual exacerbation rates in patients with severe asthma

Next Post

Association of nitrogen dioxide and other air pollution exposures with the risk of Parkinson disease

RelatedReports

Social networks play key roles in parental vaccination decisions
Infectious Disease

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

January 30, 2023
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Unvaccinated status increases risk of long COVID symptoms

January 25, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 6

January 13, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: the Future of Medicine, Neuralink, the Spotlight on Celine Dion and COVID-19 on Social Media

December 27, 2022
Next Post
Risk of dementia with air pollution exposure amplified in patients with heart disease

Association of nitrogen dioxide and other air pollution exposures with the risk of Parkinson disease

Addressing non-obesity related barriers may improve bariatric surgery effectiveness

Metabolic–bariatric surgery associated with reduced all-cause mortality compared to non-surgical management of obesity

“No Evidence of Disease Activity” may be useful goal in multiple sclerosis

Continuous infusion of hypertonic saline following traumatic brain injury does not improve neurological outcomes versus current standard of care

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options